| 英文别名： |
5-Azacytidine;4-amino-1-beta-D-ribofuranosyl-1,3,5-triazin-2(1H)-one;4-amino-1-beta-D-ribofuranosyl-s-triazin-2(1H)-one;5-AC;5 AZC;5-AZCR;Antibiotic u 18496;Azacitidine;Azacytidine;ladakamycin;u 18496;wr 183027;4-amino-1-beta-d-ribofuranosyl-s-triazin-2(1h)-on;5-triazin-2(1h)-one,4-amino-1-beta-d-ribofuranosyl-3;mylosar;nci-c01569;nsc-102816;5-AZAC;4-AMINO-1-(BETA-D-RIBOFURANOSYL)-1,3,5-TRIAZIN-2(1H)-ONE;4-AMINO-1-[(2S,3S,4R,5S)-3,4-DIHYDROXY-5-(HYDROXYMETHYL)OXOLAN-2-YL]-1,3,5-TRIAZIN-2-ONE;5-Azacytidine (Vidaza®,Mylosar®, azacytidine, NSC 102816, NSC 103-627, Ladakamycin, U 18496,);[14C]-Azacitidine;4-Amino-1-(β-D-ribofuranosyl)-1,3,5-triazin-2(1H)-one;5-AC-15N4;5-Azacitidine;5'-azacytidine;AzGR;Vidaza;4-Amino-1-beta-D-ribofuranosyl-1,3,5-triazine-2(1H)-one;5-AzaC;Ladakamycin;NSC758186;LP00035;SMR000857239;Azacitidine (5-Azacytidine);Mylosar;BRD-K03406345-001-02-1;NSC 103-627;Azacitidina;NCGC00090851-14;KBio2_005124;Azacitidine, Pharmaceutical Secondary Standard; Certified Reference Material;4-Amino-1-(beta-D-ribofuranosyl)-1,3,5-triazin-2(1H)-one;AZACITIDINE [EMA EPAR];KBio2_001742;HMS3259D19;AKOS015896938;KBio2_002556;Onureg (CC-486; oral azacitidine);Q416451;SR-01000075662-7;KBioGR_002556;5-Azacytidine, >=98% (HPLC);AZACITIDINEAZACITIDINE;U 18496;HMS2231F15;NCI-C01569;D03021;HMS2092D08;MLS002153249;Tox21_302985;4-amino-1-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1,3,5-triazin-2(1H)-one;1,3,5-Triazin-2(1H)-one, 4-amino-1-beta-D-ribofuranosyl-;NCGC00090851-06;HY-10586;1401238-97-8;AZACITIDINE [IARC];SRI-10756_12;4-Amino-1-beta-D-ribofuranosyl-1,3,5-traizin-2(1H)-one;AZACITIDINE [INN];J-700085;NCGC00090851-02;F10504;EN300-118700;DTXCID10116;6-amino-3-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1H-1,3,5-triazin-3-ium-2-one;InChI=1/C8H12N4O5/c9-7-10-2-12(8(16)11-7)6-5(15)4(14)3(1-13)17-6/h2-6,13-15H,1H2,(H2,9,11,16)/t3-,4-,5-,6-/m1/s1;KBio2_006878;UNII-M801H13NRU;5AzaC;MFCD00006539;4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2-dihydro-1,3,5-triazin-2-one;5-ACZ;M801H13NRU;Spectrum4_000922;NCGC00090851-22;4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1,3,5-triazin-2-one;azacitidine for;KBioSS_001742;cMAP_000082;HMS1921J22;320-67-2;4-Amino-1-(beta-D-ribofuranosyl)-1,3,5-triazin-2(1H)-one; Ladakamycin;AZACITIDINE [USAN];NCGC00178234-01;SRI-10756_10;NSC-102816;1,3,5-Triazin-2(1H)-one, 4-amino-1-.beta.-D-ribofuranosyl-;BRN 0620461;AZACITIDINE [MART.];Onureg;Z1515383340;AZACITIDINE (MART.);Pharmakon1600-01502111;A 2385;KBio1_000125;U-18,496;U-18496;NS-17;HMS500G07;NINDS_000125;5AE;CHEBI:2038;KBioSS_002565;BDBM50424715;AZACITIDINE [HSDB];GTPL6796;NCGC00090851-04;AS-13697;NCGC00090851-07;AM83944;SR-01000075662-3;5-Azacytidine, Hybri-Max(TM), gamma-irradiated, lyophilized powder, BioXtra, suitable for hybridoma;AZACITIDINE [JAN];AZ... |
沪公网安备31011402010658号 
